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LETTERS TO THE EDITOR
A Novel KIT Gene Missense Mutation in a Japanese Family
with Piebaldism
To the Editor:
Piebaldism is a rare autosomal dominant genetic pigmentary disorder,
characterized by congenital white hair and patches located on the
forehead, anterior trunk, and extremities. In the region of the white
patches, melanocytes are almost totally lacking, and therefore piebaldism
is thought to be due to defective proliferation or migration of
melanocytes from the neural crest during development. Recent studies
have revealed that some patients with piebaldism result from mutations
of the KIT proto-oncogene, which encodes the cellular receptor
transmembrane tyrosine kinase for mast/stem cell growth factor. In this
paper, we describe a novel KIT gene missense mutation (Thr847Pro) in
a Japanese family with piebaldism. The mutation was located in the
highly conserved cytoplasmic tyrosine kinase domain in the KIT.
The proband was a 5 y old girl who developed leukoderma on the
forehead 1 wk after birth. Physical examination revealed a depigmented
fleck in the middle of the forehead (so-called white forelock), and
various-sized depigmented patches on the abdomen and anterior
bilateral legs. The patient’s 30 y old mother exhibited similar, but
somewhat less severe symptoms, which became evident a few weeks
after birth. The patient’s maternal grandfather was also affected. To
detect KIT gene mutations in the patient, we used a genomic
polymerase chain reaction (PCR) to amplify the KIT genes. The 21
exons of the human KIT genes and their flanking sequences (Giebel
et al, 1992) were amplified with several sets of primers. The mutation
detection enhancement method was used to screen for mutation
fragments, and revealed a heteroduplex DNA, in the gel only, in exon
18 of the KIT gene. The oligonucleotide primers used for amplifying
exon 18 were 59-TGAGCTTCTGAATTAACATTA-39 (intron 17-
sense) and 59-TTGCAAAGCAGTGTTAATCAC-39 (intron 18-anti-
sense). The starting PCR product containing heteroduplex DNA was
subjected directly to DNA sequencing, which showed an A→C
transition at nucleotide position 8447, resulting in substitution of
threonine by proline at codon 847 (Fig 1). The mutation was confirmed
by the mismatch PCR method with a modified primer, which loses a
PmaC I recognition site (CACGTG) only if codon 847 contains the
mutant. The sequence of the mutated allele was 59-CCCGTT-39,
whereas that of the wild-type allele was 59-CACGTT-39. The anti-sense
primer used was 59-CATAGGACCAGACGTCACTTTCACACG-39
(exon 18). After digestion of the PCR product with PmaC I, an
undigested fragment of 130 bp and digested fragments with predicted
sizes of 103 and 27 bp were produced heterozygously from the affected
individual’s DNA, whereas only digested 103 and 27 bp fragments
were obtained from the DNA of unaffected individuals (Fig 2).
Furthermore, to confirm that the mutation was not a common
polymorphism, we examined DNA samples from 40 healthy, unrelated
Japanese individuals by the mismatch PCR method. The same mutation
was not found among the 80 alleles examined.
We have described an A to C transition at codon 847 that would
result in an amino acid change from threonine to proline. This mutation
is pathogenic and uncommon. The cytoplasmic tyrosine kinase domain
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is highly conserved among the tyrosine kinase family of growth factor
receptors and oncogenes. Indeed, the KIT, v-kit, c-fms, and platelet-
derived growth factor receptors show high homology in the tyrosine
kinase II domain. Particularly, the amino acid position that was mutated
here is always occupied by a threonine residue. Furthermore, the
amino acid sequence of codons MAPESIFNCVYT is almost invariant
among the KIT family (Yarden et al, 1987) (Fig 3).
To date, different types of KIT proto-oncogene mutations have
been reported in piebaldism (Giebel and Spritz, 1991; Spritz et al,
1993; Riva et al, 1995; Ezoe et al, 1995; Fleschman et al, 1996). These
comprise missense, frameshift, splice junction mutations, and deletions
of the KIT gene. From the viewpoint of the relationship between the
mode of KIT gene mutation and the clinical phenotype, Spritz classified
reported mutations into three groups (Spritz, 1994). Among them, the
missense mutation within the intracellular tyrosine kinase domain
produces only 25% of the normal amount of KIT receptor due to a
dominant-negative effect. Therefore, this mutation results in a relatively
Figure 1. Nucleotide sequencing demonstrating a point mutation in
one of the KIT alleles. The arrows indicate the position of heterozygous
A→C transition at nucleotide position 8447, resulting in substitution of
threonine by proline at codon 847: (a) patient; (b) normal control.
Figure 2. Confirmation of the point mutation by mismatch PCR using
a modified primer. After digestion with PmaC I, an undigested fragment of
130 bp and digested fragments with predicted sizes of 103 and 27 bp were
produced heterozygously from only the affected individual’s DNA.
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Figure 3. A highly conserved amino acid sequence in the intracellular
tyrosine kinase domain of the KIT family. Note that the sequence of
MAPESIFNCVYT is almost invariant among the KIT family. Conserved amino
acids are boxed. The arrow indicates the mutation position. The threonine
mutated here is a strictly conserved amino acid residue.
severe phenotype, as compared with the other type of mutations. On
the basis of the above findings, Spritz stated that a hierarchical paradigm
of KIT mutation accounts for a graded series of dominant phenotypes
of piebaldism (Spritz, 1994). Our patient exhibited a typical and
relatively severe piebaldism phenotype. Therefore, our results provide
supportive evidence that a missense mutation within the tyrosine kinase
domain produces a severe phenotype. Incidentally, Ezoe has reported
that pathologic KIT gene mutations or gene deletions were detected
in only 75% of patients with typical piebaldism (Ezoe et al, 1995). It
is important to examine more patients with piebaldism and investigate
the molecular defects in the KIT gene.
Autoantibodies from a Patient with Paraneoplastic Pemphigus
Bind Periplakin, a Novel Member of the Plakin Family
To the Editor:
Paraneoplastic pemphigus (PNP) is a mucocutaneous disorder associated
with neoplasia (Anhalt et al, 1990). It is characterized by mucosal
erosions, polymorphous cutaneous lesions, and variable histologic
features. PNP patients have in situ bound and circulating autoantibodies
that bind to stratified and nonstratified epithelia (Anhalt et al, 1990;
Oursler et al, 1992). Sera from affected patients immunoprecipitate a
complex of proteins with an apparent molecular mass of 250 kDa,
230 kDa, 210 kDa, 190 kDa, 170 kDa, and 135 kDa in a variable
pattern (Anhalt et al, 1990; Oursler et al, 1992; Hashimoto et al, 1995).
It has been suggested that the detected 230 kDa is the bullous
pemphigoid antigen 230 (BP230), the proteins of 250 kDa and 210 kDa
correspond to desmoplakin I (DPI) and II (DPII), respectively, while
the 135 kDa is desmoglein 3 (Anhalt et al, 1990; Oursler et al, 1992;
Hashimoto et al, 1995). Recent studies, however, indicate that the
210 kDa protein bound by some patients’ sera is not DPII, but
envoplakin (ENV) (Kim et al, 1997). We have here investigated the
identity of the proteins targeted by the autoantibodies from a patient
with PNP by combined immunoblot and immunoprecipitation studies.
The 45 y old Caucasian patient fulfilled the criteria of PNP because
he exhibited: (i) a polymorphous eruption with bullous and erosive
lesions of the oral cavity, conjunctivae, trunk, extremities, and genital
area, in association with a history of relapsing Castleman’s tumor;
(ii) histologically, scattered necrotic keratinocytes, vacuolar interface
changes, and a lichenoid infiltration in the upper dermis; (iii) immuno-
pathologically, deposits of C3 in the epidermal basement membrane
associated with deposits of IgG and C3 in the epidermal intercellular
spaces, as well as circulating IgG antibodies that bound the cell
surfaces of human epidermis, stratified squamous epithelium of monkey
esophagus, and transitional epithelium of rat urinary bladder. To
investigate the reactivity of this patient’s serum, mouse IgG monoclonal
antibody (MoAb) against desmoplakin (Boehringer Mannheim AG,
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Rotkreuz, Switzerland) and MoAb against desmoglein 1 (Progen,
Biotechnik GmbH, Heidelberg, Germany) were used. The rabbit anti-
serum CR1 and the anti-serum CR3 against the COOH-terminus of
ENV and periplakin (PER), respectively, were kindly provided by Dr.
F.M. Watt (Imperial Cancer Research Fund, London, U.K.) (Ruhrberg
et al, 1996, 1997). The anti-serum against the COOH-terminal domain
of BP230 was a gift of Dr. J.R. Stanley (Department of Dermatology,
University of Pennsylvania, Philadelphia, PA). Peroxydase-conjugated
goat anti-human IgG (H 1 L) antibody (Institut Pasteur, Marnes la
Coquette, France), goat anti-mouse Ig (Amersham Life Sciences,
Zu¨rich, Switzerland), and goat anti-rabbit IgG (Cappel, West Chester,
PA) were purchased. Immunoblotting studies using bovine tongue
extracts were performed as previously described (Rybojad et al, 1993).
For immunoprecipitation studies cultured human keratinocytes were
incubated with modified Eagle’s medium without methionine and
cysteine (Gibco BRL, Basel, Switzerland) for 1 h at 37°C, then labeled
with 100 µCi (35S) methionine/cysteine (Amersham) per ml for 6 h,
washed, and lyzed with 1% NP-40 in 25 mM Tris-HCl (pH 7.5),
4 mM ethylenediamine tetraacetic acid, 100 mM NaCl, 1 mM
phenylmethanesulfonyl fluoride, 10 µg leupeptin per ml, and 10 µg
soybean trypsin inhibitor per ml. The lysates were clarified by centrifu-
gation and precleared with Protein A-Sepharose CL-4B (Pharmacia
LKB Biotechnology, Uppsala, Sweden). Samples of precleared lysates
were immunoprecipitated with antibodies previously bound to protein
A-Sepharose or to Protein A-Sepharose to which rabbit anti-mouse
IgG was attached (Borradori et al, 1997). The immunoprecipitates
were washed with lysis buffer and with phosphate buffered saline, after
which they were resuspended in sodium dodecyl sulfate-sample buffer,
analyzed on a 5% sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis under reducing condition, and processed for fluorography or,
alternatively, electrophoretically transferred to a nitrocellulose sheet for
immunoblotting.
Consistent with previous studies in PNP, the patient’s serum con-
